<SEC-DOCUMENT>0000842023-13-000018.txt : 20130723
<SEC-HEADER>0000842023-13-000018.hdr.sgml : 20130723
<ACCEPTANCE-DATETIME>20130723100304
ACCESSION NUMBER:		0000842023-13-000018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130722
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130723
DATE AS OF CHANGE:		20130723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TECHNE CORP /MN/
		CENTRAL INDEX KEY:			0000842023
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				411427402
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17272
		FILM NUMBER:		13980484

	BUSINESS ADDRESS:	
		STREET 1:		614 MCKINLEY PL N E
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		6123798854

	MAIL ADDRESS:	
		STREET 1:		614 MCKINLEY PLACE NE
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8bionostics.txt
<DESCRIPTION>8-K
<TEXT>

                                   UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                               Washington, DC 20549



                                      FORM 8-K


                                   CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

          Date of Report (Date of earliest event reported): July 22, 2013

                                 TECHNE CORPORATION
                    (Exact Name of Registrant as Specified in its Charter)

       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                 614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>


Item 8.01 Other Events

     On July 22, 2013, R&D Systems, Inc. ("R&D Systems"), a
Minnesota corporation and wholly-owned subsidiary of Techne Corporation,
acquired all of the outstanding stock of Bionostics Holdings Limited ("BHL"), a
United Kingdom company from the shareholders of BHL.  Through the
acquisition of BHL, R&D Systems also acquired BHL's subsidiary Bionostics, Inc.,
a Massachusetts corporation ("Bionostics").

     R&D Systems acquired the shares of BHL for total consideration of
approximately $104 million in cash, of which $13 million will be held in escrow
for 18 months to secure indemnity obligations of the shareholders of BHL
contained in the Share Purchase Agreement for the acquisition.  The purchase
price may be adjusted post-closing based on the final level of working capital
of Bionostics at closing.

     A copy of the press release announcing the acquisition is filed
herewith as Exhibit 99.1.



Item 9.01 Financial Statements and Exhibits

	99.1	Press Release, dated July 22, 2013.




                                SIGNATURE

	Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.




					TECHNE CORPORATION

Date: July 23, 2013		By:	 /s/ Charles R. Kummeth
                                        ------------------------------------
					Charles R. Kummeth
					President and Chief Executive Officer





                               EXHIBIT INDEX


    Exhibit No. Description
    ----------- -----------

	99.1	Press Release, dated July 22, 2013.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bionosticsclosing.txt
<DESCRIPTION>PRESS RELEASE DATED JULY 22, 2013
<TEXT>

           TECHNE CORPORATION ANNOUNCES ACQUISITION COMPLETION

Minneapolis - July 22, 2013 - Techne Corporation (NASDAQ: TECH) (Techne)
announced today that it has finalized its previously announced acquisition of
Bionostics Holdings Limited and its operating subsidiary Bionostics, Inc.
(Bionostics). Bionostics was acquired for approximately $104 million in cash,
subject to adjustments following closing based on the final level of working
capital.

Bionostics is a global leader in the development, manufacture and
distribution of control solutions that verify the proper operation of in
vitro diagnostic (IVD) devices primarily utilized in point of care blood
glucose and blood gas testing.  Bionostics has strategic supply relationships
with virtually all global IVD device Original Equipment Manufacturers (OEMs).

Techne, through its subsidiaries R&D Systems and R&D Systems Europe, is
engaged in the development, manufacture and sale of biotechnology products
and hematology calibrators and controls.  Bionostics and Techne's Hematology
Division will collectively operate under a new Clinical Controls Division of
R&D Systems after close of the transaction.

Bionostics was founded in 1981 and is based in Devens, Massachusetts.  Its
controls are proprietary device-specific formulations which require FDA
510(k) approval.  Like the products made by R&D Systems' Clinical Controls
Division, each control is also a component of the OEM's 510(k), making
Bionostics' controls integral to each diagnostic device.  Controls for blood
glucose and blood gas devices are the largest portion of Bionostics'
business.  Bionostics recently launched coagulation device control products
and is developing new controls for other growing diagnostic uses,
particularly controls for cholesterol and HbA1c point-of-care testing (POCT)
devices.

Fredrikson & Byron, P.A. served as legal counsel to Techne.

-----------------------------------------

TECHNE Corporation and Subsidiaries (the Company) are engaged in the
development, manufacture and sale of biotechnology products and hematology
calibrators and controls. These activities are conducted through the
Company's two operating subsidiaries: Research and Diagnostic Systems, Inc.
(R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D
Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of
biological products. R&D Systems has three subsidiaries: BiosPacific, Inc.
(BiosPacific), located in Emeryville, California, Boston Biochem, Inc.,
located in Cambridge, Massachusetts, and R&D Systems China Co. Ltd., (R&D
China), located in Shanghai, China. BiosPacific is a worldwide supplier of
biologics to manufacturers of in vitro diagnostic systems and
immunodiagnostic kits. Boston Biochem is a leading developer and manufacturer
of ubiquitin-related research products. R&D China and R&D Europe distribute
biotechnology products. R&D Europe has two subsidiaries: Tocris Holdings Ltd.
(Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation.
Tocris is a leading supplier of chemical reagents for non-clinical life
science research.

Contact:   Greg Melsen, Chief Financial Officer
           Kathy Backes, Controller
           (612) 379-8854



</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
